FR3035790A3 - DENTAL PREPARATION BASED ON HYALURONANE AND OCTENIDINE DICHLORHYDRATE - Google Patents

Abstract

The present invention relates to a dental composition in the form of a lyophilizate or a gel based on a physiologically acceptable salt of hyaluronic acid and an antiseptic (octenidine dihydrochloride), optionally one or more other polysaccharides and a physiologically acceptable inorganic salt, which is suitable for the treatment and prevention of dental complications, for example for the treatment and prevention of alveolar osteitis, the treatment of gum healing after removal of tartar , for the treatment of injuries of the oral mucosa and tongue or other types of injuries and lesions of the oral cavity. The dental composition or preparation is characterized in that it contains a physiologically acceptable salt of hyaluronic acid and octenidine dihydrochloride in a weight ratio of 100: 1 to 2000: 1 and is in the form of lyophilizate or gel.

Description

TECHNICAL FIELD OF THE INVENTION The technical solution relates to a dental composition in the form of a lyophilizate or a gel based on a physiologically acceptable salt of hyaluronic acid and an antiseptic (dihydrochloride). octenidine), optionally one or more other polysaccharides and a physiologically acceptable inorganic salt, which is suitable for the treatment and prevention of dental complications, for example for the treatment and prevention of alveolar osteitis, the treatment scarring of the gums after the removal of tartar, for the treatment of wounds of the oral mucosa and tongue or other types of wounds and lesions of the oral cavity. BACKGROUND OF THE INVENTION Alveolar osteitis (alveolitis sicca, dry alveolitis, dry bed, fibrinolytic alveolitis, post-extraction syndrome) is a complication after tooth extraction, which leads to non-training or the disintegration of blood coagulation. It most often affects the beds in the lower jaw. The bed is empty, gray in color, very painful. The incidence of alveolar osteitis after wisdom tooth extraction is up to 35%. Alveolar osteitis means partial or complete disintegration of the blood clot due to fibrinolysis (conversion of plasminogen to plasmin) with a microbial effect at the wall of the extraction wound bed. Clinically, it is characterized mainly by an intense pain that is difficult to overcome, not only in the location of the extraction wound, but also in the entire jaw, or even in the ear. The exudation is not present, the dental bed is empty, without clots, or is filled with leftover food. The treatment consists of an irrigation (enema) of the extraction wound to remove the necrotic excochlear bed, re-hemorrhaging the wound and initiating healing. It is possible to use a therapeutic intra-alveolar agent after the excochleation and irrigation of the bed. Preventive measures are of great importance, including several options, which should reduce the formation of osteitis alveolar, using general or local remedies. To all therapeutic agents administered belong steroids and prophylactic antibiotics. Antibiotic prophylaxis is part of very common preventive treatment processes, providing means that provide an antimicrobial environment and prevent the development of the disease. A single dose before exercise is preferred to ensure the systemic presence of the antibiotic at the time of the surgery. Lincosamides are the most frequently recommended (clindamycin), other antibiotics in the penicillin (amoxicillin) range, and tetracycline. With regard to antibiotics, the indications can not be precisely defined, however prophylactic administration of antibiotics is appropriate for treating wisdom teeth where there will be a prolonged complicated procedure requiring significant preparation of the bone.

The topical therapeutic compositions are administered in two forms, as antiseptic rinses of the oral cavity, or intra-alveolar route. For rinsing, saline solutions, hydrogen peroxide (3%) and hexetidine or chlorhexidine compositions are used.

Chlorhexidine is used in the form of solutions (at a concentration of 0.2 and 0.12%) and gel (at a concentration of 1 and 0.5%), and currently also in the form of tablets and tablets. aerosols. The advantage of chlorhexidine is its binding to the surface structure of epithelial cells of the oral mucosa. After rinsing, about 30% remains bound. This quantity is gradually released into the saliva and thus prolongs its action. The most frequently recommended use of chlorhexidine is a mouthwash immediately before surgery. Similar irrigation is used 2x daily for 7 days after surgery. Numerous studies show the effect of washes undertaken where there is a reduction in the incidence of alveolitis of nearly 50%. Intra-alveolar prophylaxis includes the therapeutic administration of the antiseptic / antimicrobial agent directly into the extraction wound. A very suitable method is the use of chlorhexidine gel in the coiled at the end of the run. The gel is applied in a single dose. Another variant is a so-called open method that allows an antiseptic action of iodoform. The open method is to leave the extraction wound open but being buffered in the crown portion with the iodoform drain. The antiseptic effect protects the resulting blood clot with subsequent healing. The drain should be changed again after 3-5 days against another shorter one, and the extraction wound is only rinsed with saline solution. After 2 weeks, the drain is removed. The disadvantage of this method is the need to change the drain during several inspections, which significantly interferes with the postoperative comfort of the patient, and also an unpleasant smell of iodoform. Another option is to introduce a drain impregnated with Framykoin (Pamycon - registered trademark) or sprinkle the wound with benzocaine. The significant and antiseptic analgesic for dental use is clove oil with its eugenol active ingredient. In veterinary medicine, soft tissues of the oral cavity have often been found caused by excessive production and deposition of tartar, especially in dogs and cats. The cause of excessive scale deposition is not only a genetic predisposition, but also the composition of the diet and the method (or complete absence) of the caregiver of the teeth and oral cavity of the animal. . Tartar can be classified according to its location as supragingival and subgingival. Supragingival calculus is placed above the gums, on the crowns of the teeth, and can cover a large area of the tooth. Subgingival calculus is formed below the edge of the gingiva in the gingival crevice or periodontal pocket. It creates deposits on the walls of the root, which is difficult to remove. Tartar can be removed by ultrasound, either manually or with a combination of both. In veterinary medicine, ultrasound teeth cleaning is used in most cases under general anesthesia. By using an ultrasound device, even coarse and hard scale deposits can be removed. When using ultrasound machines, the soft tissues in the mouth can also be damaged and it is therefore appropriate to treat the affected gums and promote healing. This can be achieved by rinsing with antiseptic solutions, gels or pastes containing substances having a disinfecting effect (for example in humans Gengigel gel, Corsodyl gel 1% gel Curasept ADS Periodontal, the Phyteneo Neocide gel - registered trademarks In veterinary medicine for example Gingisan AUV gel, Stomodin gel - registered trademarks). Some animal products contain natural substances with an antibacterial effect or substances that accelerate healing (for example Hexocare Stomaclean ™ dental gel and others). The hyaluronic acid oral gel provides proactive protection against gum disease and promotes natural healing of damaged tissue and inflammation in the oral cavity. Hyaluronan 10 also stimulates the formation of new healthy tissue. Here is another possible indication for the use of antiseptic and curative products to promote the rapid regeneration of the gums. The use of hyaluronic acid in the dental field for the healing of mucous membranes is known. Hyaluronan is, for example, the basis of the preparations of the Gengigel-trademark line which are intended for preventive care and support in the treatment of gingivitis-related conditions and a dental suspension apparatus. In combination with bovine collagen, hyaluronic acid is a Hypro-Sorb Z-registered trademark, which serves as a haemostat after tooth extraction. Octenidine dihydrochloride is part of the oral hygiene used in Octenidol mouthwash - registered trademark, otherwise it is part of preparations for skin antisepsis and wound healing, for example in Octenisept, Octenilin - brands deposited etc.

European Patent Application EP2401914 discloses an antiseptic antimicrobial mixture for wounds and mucous membranes. The preparation contains alkane bispyridinium (octenidine dihydrochloride), a humectant and water. A preferred wetting agent is glycerol. In addition to the solution, the patent application does not mention other forms of preparations. The content of octenidine dihydrochloride relative to the hydration component is greater, which may result, after prolonged administration, in irritation of the mucous membranes or skin. International Patent Application WO2009032406 discloses a composition for the treatment and prevention of xerostomia and related pathology, for example bacterial infections, dental caries and the like. It is a mixture containing a surfactant, an antimicrobial substance and an adhesive. The preparation is available in the form of toothpaste, mouthwash or oral spray. The disadvantage of this solution is the high content of antiseptics that can irritate, so the described solution is only suitable for short-term application.

International Patent Application WO2006105196 describes a composition whose main component is diindolylmethane, which may be present in combination with another anti-inflammatory or anti-bacterial agent. The composition may be administered in the form of capsules, tablets, dentifrices, oral gels, mouthwashes, lozenges and the like.

The product has been designed for the treatment of oral mucosa with a deteriorated structure, for example with periodontitis or gingivitis, to prevent and stop bone loss (osteopenia, osteoporosis) or for the treatment of chronic inflammation of the buccal mucosa. the mucosa. International Patent Application WO2012174076 discloses a polymetallic complex and a carrier suitable for oral use. The complex is a mixture of a polyfunctional compound (eg, polycarboxylic acid, polyamino acids, etc.) of two or more elements, if necessary, other active ingredients. A preferred complex is copper-zinc malonate. The preferred forms are solution, foam, sticks and ointments. International Patent Application WO2012073191 discloses a mucosal regeneration composition containing choline alfoscerate and hyaluronan of high molecular weight (0.8-4 MDa). In addition, it may contain other active ingredients, for example silver, aloe vera, allantoin, chlorhexidine or benzalkonium chloride. European Patent Application EP2520279 discloses a medical device for dental use in the form of heat-reversible gel. The composition consists of water, a topically active agent, thickeners, and a mucoadhesive component which improves adhesion in the oral mucosa or tooth enamel, which increases the presence of the preparation at the place of destination. It is hyaluronic acid or its salt which represents the mucoadhesive component, as the thickening agent is a poloxamer and the active substance is in the group consisting of disinfectants, fluoride salts, antioxidants, local anesthetics, antibiotics or anti-inflammatory agents. International Patent Application WO2013079443 3035790 discloses a composition for bone regeneration in mammals, preferably jaw bones in humans, for example during periodontitis. The composition consists of a binder, a granule and hyaluronic acid. Granules such as aragonite, bioceramic, bio-glass or allogeneic, autogenous or xenogeneic bone mass are used. The binder is collagen, possibly another "fibrin glue". International Patent Applications WO2013029796, WO2013029797 and WO2013029798 disclose a multilayer structure dressing comprising a textile layer, activated carbon and another specific layer. It can be either a hydrocolloid or a breathable layer. The hydrocolloid may be hyaluronan. The composition may further contain an active antiseptic substance or other active agents (eg, allantoin, bromelain, riboflavin, etc.). Object of the Invention The invention relates to a dental composition or preparation based on hyaluronic acid (hyaluronan) and octenidine dihydrochloride, which is characterized in that it contains a physiologically acceptable salt of hyaluronic acid and octenidine dihydrochloride, in a ratio by weight of 100: 1 to 2000: 1, preferably 400: 1 to 800: 1, more preferably 500: 1, and which is in the form of a lyophilisate or a gel. The ratio by weight indicated above 100: 1 to 2000: 1 of the two active ingredients has a range which guarantees both the safety and effectiveness of the invention. The advantage of the dental preparation in the form of lyophilisate or gel is its ease of handling and, for the lyophilizate, the personalized contours and in addition the possibility of forming a buffer if necessary, for example of the form corresponding to the extraction wound 30 after a tooth extraction, since the hyaluronan is applied very well and remains with its longer adhesiveness in the wound or on the oral mucosa. The preparation according to the invention in the form of a lyophilizate and a gel can be very well adjusted with respect to the exact content of octenidine dihydrochloride by adjusting it to the range which is effective, without being irritating. . By the above preferred ratio of 400: 1 to 800: 1, preferably 500: 1, wound healing is not impaired, while efficacy against both G-bacteria + and G- and the yeast is very high. With the preparation according to the invention in the form of a lyophilizate and a gel can also be carried out a pH adjustment with accuracy corresponding to the pH of the saliva of the target mammal, such as dogs, cats, which contributes to the compatibility with the environment and thus contributes to a slow elimination of the substance in the region of application.

According to a preferred technical embodiment of the invention, the physiologically acceptable salt of hyaluronic acid in the composition is selected from the group consisting of alkali metal ions or alkaline earth ions, preferably Na, KE, Ca2 + or Mg2 ±. In addition, according to a preferred technical embodiment of the invention, the molecular weight of the physiologically acceptable salt of hyaluronic acid in the composition is in the range 2 x 105 to 2.5 x 106 g / mol, preferably between 1 x 106 to 2.5 x 106 g / mol, due to high hydration capacity, respectively a slow degradation of the wound space.

According to yet another preferred technical embodiment, the composition of the invention preferably further comprises at least one auxiliary polysaccharide and / or at least one physiologically acceptable inorganic salt, which are useful for the treatment and prevention of alveolar osteitis or other complications after extraction of the tooth in stomatology, or to treat other types of wounds and damage to the mucous membranes, for example for the treatment of the gums after descaling. The auxiliary polysaccharide is preferably selected from the group consisting of carboxymethylcellulose (CMC), hydroxyethylcellulose (HEC), hydroxypropylmethylcellulose (HPMC), alginate, or polyvinylpyrrolidone (PVP). In yet another preferred technical embodiment of the invention, the weight ratio of the physiologically acceptable salt of the hyaluronic acid and at least one adjuvant of the (auxiliary) polysaccharide is in the range of 80:20 to 20:80. preferably between 75:25 and 40:60.

The physiologically acceptable inorganic salt is preferably calcium chloride, which has a dual function and also helps to stop bleeding from the wound and also contributes to the formation of calcium salt of hyaluronic acid, which has a half-life of the elimination longer than the sodium salt. The preferred concentration is given by the molar ratio between the carboxyl groups of hyaluronic acid, and calcium ions, which must be in the range of 1: 1 to 1: 0.1, preferably in the range of 1 0.4. The total concentration of polysaccharides in the composition according to the technical solution is in the range of 1 to 5% by weight, preferably in the range of 4 to 5% by weight in the gel. According to another technical embodiment of the invention, the preparation is in the form of a buffer in the form of, or consisting of, a lyophilizate. For the creation of lyophilizate, initial solutions are also suitable at a concentration of 1 to 5% by weight, the preferred range, however, being 2 to 3.5% by weight. Most preferred from the point of view of moldability and at the same time the duration of the presence in the wound is a concentration of 2.5% by weight in the case of hyaluronic acid with a Mw in the range. from 1.5 to 1.8 x 106 g / mol. The term "total concentration of polysaccharides" means the cumulative concentration of the physiologically acceptable salt of hyaluronic acid, and all the other excipients present in the polysaccharide preparation according to the invention in gel form. It is expressed in% by weight. EXAMPLES EXAMPLE 1 Lyophilizate with Hyaluronan, Octenidine Dihydrochloride and Calcium Chloride To 24.271 ml of water for injection, 16 μl of 10% solution are first added using a pipette. of octenidine dihydrochloride in ethanol, then 92 mg of calcium chloride dihydrate are added and the solution should be thoroughly mixed. To this solution, 625 mg of sodium hyaluronan having a molecular weight of 1.78 × 10 6 g / mol is added progressively with stirring and is allowed to disperse completely. Then it is advisable to let the bubbles escape from the solution. The total concentration of polysaccharides in the initial solution is 2.5% by weight. The resulting viscous solution is assayed at 1.2 ml in a PE blister having the oval-shaped dimples. The filled blister is inserted into a lyophilizer, frozen, then lyophilized, if necessary, or optionally frozen in a freezer at a temperature below -50 ° C, then placed in a lyophilizer and freeze-dried. The blister is closed with a paper envelope and the lyophilisates are sterilized with ethylene oxide. The lyophilizates are intended for the treatment or prevention of alveolar osteitis after tooth extraction and can be shaped as needed, for example depending on the size of the cavity. The lyophilizate can be adapted for example with a scalpel to obtain a smaller size, for example a wafer, and used for the treatment of other injuries of the oral mucosa, for example mouth ulcers.

EXAMPLE 2 Lyophilisate with hyaluronan and octenidine dihydrochloride To 24.171 ml of water for injection, 21 μl of a solution of 10% octenidine dihydrochloride solution was added via pipette to the reaction medium. ethanol. The solution must be thoroughly mixed. To this solution, 812.5 mg of sodium hyaluronan with a molecular weight of 1 x 106 g / mol is gradually added with stirring and allowed to disperse thoroughly. Then it is advisable to let the bubbles escape from the solution. The total concentration of polysaccharides in the initial solution is 3.25% by weight. The resulting viscous solution is assayed at 1.2 ml in a PE blister having oval-shaped dimples. The filled blister is inserted in a lyophilizer, frozen, then lyophilized, if necessary or possibly frozen in a freezer at a temperature below -50 ° C., then placed in a lyophilizer and freeze-dried. The blister is closed with a paper wrapper and the lyophilizates are sterilized with ethylene oxide. Lyophilisates are intended for the treatment or prevention of alveolar osteitis after tooth extraction and can be shaped as needed, for example depending on the size of the cavity. The lyophilizate can be adapted for example with a scalpel to obtain a smaller size, for example a wafer, and used for the treatment of other injuries of the oral mucosa, for example mouth ulcers. EXAMPLE 3 Lyophilizate with Hyaluronan, Octenidine Dihydrochloride, Calcium Chloride and Hydroxylethylcellulose To 24.703 ml of water for injection, 13 μl of solution for solution was added by pipette. 10% octenidine dihydrochloride in ethanol, followed by the addition of 37 mg calcium chloride dihydrate and the solution should be thoroughly mixed. To this solution, 150 mg of hydroxyethylcellulose and 100 mg of sodium hyaluronan of molecular weight 2.5 x 10 6 g / mol are added gradually with stirring while being stirred and allowed to disperse completely. Then, it is advisable to let the 5 bubbles of the solution escape. The total concentration of polysaccharides in the starting solution is 1% by weight. The resulting viscous solution is assayed at 1.2 ml in a PE blister having oval-shaped dimples. The filled blister is inserted into a lyophilizer, frozen, then lyophilized, if necessary, or optionally frozen in a freezer at a temperature below -50 ° C., then placed in a freeze-dryer and lyophilized. The blister is closed with a paper envelope and the lyophilisates are sterilized with ethylene oxide. Lyophilisates are intended for the treatment or prevention of alveolar osteitis after tooth extraction and may be shaped as needed, for example depending on the size of the cavity. The lyophilizate can be adapted for example with a scalpel for a smaller size, for example a wafer, and used for the treatment of other injuries of the oral mucosa, for example mouth ulcers. Example 4 Lyophilizate with hyaluronan, octenidine dihydrochloride, calcium chloride and hydroxymethylcellulose. To 23.708 ml of water for injection, a solution of 10% octenidine dihydrochloride solution in ethanol was added using a pipette, followed by the addition of 37 mg of calcium chloride dihydrate and The solution must be thoroughly mixed. 250 mg of HPMC and 1 mg of sodium hyaluronan with a molecular weight of 0.2 × 10 6 g / mol are added progressively with stirring to this solution and it is allowed to disperse completely. Then it is advisable to let the bubbles escape from the solution. The total concentration of polysaccharides in the initial solution is 5% by weight. The resulting viscous solution is assayed at 1.2 ml in a PE blister having oval-shaped dimples. The filled blister is inserted in a lyophilizer, frozen, then lyophilized, if necessary, or possibly frozen in a freezer at a temperature below -50 ° C., then placed in a lyophilizer and freeze-dried. The blister is closed by a paper envelope and the lyophilizates are sterilized with ethylene oxide. The lyophilizates are intended for the treatment or prevention of alveolar osteitis after tooth extraction and can be shaped as required, for example depending on the size of the cavity. The lyophilizate can be adapted for example with a scalpel for a smaller size, for example a wafer, and used for the treatment of other injuries of the oral mucosa, for example mouth ulcers.

EXAMPLE 5 Gel with hyaluronan and octenidine dihydrochloride To 23.688 ml of water for injection, 8 μl of 10% solution of octenidine dihydrochloride was added by pipette into ethanol. The solution must then be mixed thoroughly. To this solution, 1.25 g of sodium hyaluronan having a molecular weight of 0.2 x 10 6 g / mol is gradually added with stirring and allowed to disperse thoroughly. The resulting viscous solution is metered into suitable containers, for example glass bottles, tubes or syringes. Then it is sterilized by moist heat. The total concentration of polysaccharides in the gel is 5% by weight. The gel is used, for example, for the treatment of the gums after the removal of calculus, the treatment or the prevention of the treatment of alveolar osteitis or other damage to the mucosa or the skin, even in the case of infections microbial.

Example 6 Gel with hyaluronan and octenidine dihydrochloride, calcium chloride and polyvinylpyrrolidone. To 24,270 ml of water for injection, 16 μl of 10% solution of octenidine dihydrochloride in ethanol was pipetted and then 92 mg of calcium chloride dihydrate added and solution must be thoroughly mixed. 175 mg of the crosslinked polyvinylpyrrolidone (Kollidon 30 - registered trademark) are added gradually to this solution while stirring. Then, the pH is adjusted by the addition of 2.5 μl of 5M NaOH and the solution is allowed to mix well.

Finally, 450 mg of sodium hyaluronan having a molecular weight of 1.78 × 10 6 g / mol is gradually added and once more dispersed thoroughly. The resulting viscous solution is metered into suitable containers, for example glass bottles, tubes or syringes. Then it is sterilized by moist heat. The total concentration of polysaccharides in the gel is 2.5% by weight. The gel is intended for veterinary applications, for example for the treatment of gums after the removal of scale, especially for dogs and cats, because of its pH which is in the range of 7.4. ± 0.4, which corresponds exactly to the salivary pH in dogs and cats. EXAMPLE 7 Gel with hyaluronan and octenidine dihydrochloride and carboxymethylcellulose To 24.750 ml of water for injection, 6 μl of 10% solution of octenidine dihydrochloride are added by pipette. in ethanol. The solution must be thoroughly mixed. To this solution, 150 mg of carboxymethylcellulose and 100 mg of sodium hyaluronan of molecular weight 2.5 x 10 6 g / mol are gradually added with stirring and allowed to disperse completely. The resulting viscous solution is metered into suitable containers, for example glass bottles, tubes or syringes. Then sterilized by moist heat. The total concentration of polysaccharides in the gel is 1% by weight. The gel is used, for example, for treating the gingiva after calculus removal, treating or preventing the treatment of alveolar osteitis or other damage to the mucosa or skin, even in the case of microbial infections.

Example 8 Gel with hyaluronan, hydroxyethylcellulose, calcium chloride, octenidine dihydrochloride and benzalkonium chloride as a BAC preservative. To 24.342 ml of water for injection, 16 μl of a 10% solution of octenidine dihydrochloride in ethanol was added by pipette. The solution must be thoroughly mixed. To this solution, 150 mg of hydroxyethylcellulose are added gradually with stirring. Then, 16 mg of calcium chloride dihydrate is added. The solution must be mixed thoroughly. 2.5 μl of benzalkonium chloride are then added. The solution is mixed and then the pH is adjusted by the addition of 1.7 g of 5M NaOH. Finally, 450 mg of sodium hyaluronan having a molecular weight of 1.78 × 10 6 g / mol is gradually added with stirring and allowed to disperse completely. The viscous solution is dosed in suitable containers, for example glass bottles, tubes or syringes. The total concentration of polysaccharides in the gel is 2.4% by weight. The gel is intended for veterinary applications, for example for the treatment of gums after calculus removal, especially for dogs and cats, because of its pH which is in the range of 7.4. ± 0.4, which corresponds exactly to the salivary pH in dogs and cats. Example 9 Gel with hyaluronan, octenidine dihydrochloride, calcium chloride, hydroxyethylcellulose and polyvinylpyrrolidone To 23.68 ml water for injection, pipette 30.4 μl of 10% solution of octenidine dihydrochloride in ethanol, then the pH is adjusted by the addition of 2.4 μl of 5M NaOH. You have to mix carefully. 200 mg of hydroxyethylcellulose and 750 mg of crosslinked polyvinylpyrrolidone (Kollidon 90F - registered trademark) are added progressively with stirring to this solution. Afterwards, 92 mg of calcium chloride dihydrate are added and the solution should be mixed thoroughly. Finally, 250 mg of sodium hyaluronan having a molecular weight of 1.78 x 10 6 g / mol is gradually added and allowed to disperse to the bottom again. The total concentration of polysaccharides in the gel is 4.8% by weight. EXAMPLE 10 Gel with hyaluronan, octenidine dihydrochloride, calcium chloride, alginate and polyvinylpyrrolidone To 23.69 ml water for injection, pipette 30.4 μl of 10% solution of octenidine dihydrochloride in ethanol, then the pH is adjusted by addition of 2 μl 5M NaOH. You have to mix them carefully. To this solution, 250 mg of alginate and 700 mg of the cross-linked polyvinylpyrrolidone (Kollidon 90F - registered trademark) are gradually added with stirring. After careful mixing of the solution, 92 mg calcium chloride dihydrate is added and the solution should be mixed thoroughly. Finally, 250 mg of sodium hyaluronan having a molecular weight of 2.5 x 10 6 g / mol is gradually added and allowed to disperse thoroughly. The total concentration of polysaccharides in the gel is 4.8% by weight. Of course, the invention is not limited to the embodiments described. Modifications are possible, particularly from the point of view of the constitution of the various elements or by substitution of technical equivalents, without departing from the scope of protection of the invention.

Claims (12)

REVENDICATIONS1. Dental preparation based on hyaluronan and octenidine dihydrochloride, characterized in that it contains a physiologically acceptable salt of hyaluronic acid and octenidine dihydrochloride, in a ratio by weight of 100: 1 to 2000: 1 and in the form of a lyophilizate or a gel. 2. Preparation according to claim 1, characterized in that the physiologically acceptable salt of hyaluronic acid is selected from the group consisting of alkali metal ions or alkaline earth ions, preferably Na +, I (±, Ca2 + or Mg2 + . 3. Preparation according to claim 1 or claim 2, characterized in that the molecular weight of the physiologically acceptable salt of hyaluronic acid is in the range of 2 x 105 to 2.5 x 106 g / mol. The preparation according to any one of the preceding claims 1 to 3, characterized in that the molecular weight of the physiologically acceptable salt of hyaluronic acid is in the range of 1x106 to 2.5x106 g / mol. 5. Preparation according to any one of the preceding claims 1 to 4, characterized in that it contains a physiologically acceptable salt of hyaluronic acid and octenidine dihydrochloride in a weight ratio of 400: 1 to 800: 1, preferably 500: 1 6. Preparation according to any one of claims 1 to 5, characterized in that it further comprises at least one auxiliary polysaccharide selected from the group comprising carboxymethylcellulose, hydroxyethylcellulose, hydroxypropylmethylcellulose, alginate, or polyvinylpyrrolidone and / or at least one physiologically acceptable inorganic salt. 7. Preparation according to claim 6, characterized in that the weight ratio of the physiologically acceptable salt of the hyaluronic acid and at least one adjuvant of the polysaccharide is in the range of 80:20 to 20:80, preferably 75 : 25 and 40:60. 8. Preparation according to claim 6, characterized in that the physiologically acceptable inorganic salt is calcium chloride. 3035790 - 15 - 9. Preparation according to claim 8, characterized in that the molar ratio of carboxyl groups of hyaluronic acid, and calcium ions is in the range of 1: 1 to 1: 0.1. 10. Preparation according to claim 9, characterized in that the molar ratio of carboxyl groups of hyaluronic acid and calcium ions is preferably 1: 0.4. 11. Preparation according to any one of the preceding claims 1 to 10, characterized in that it is in the form of a buffer in the form of lyophilisate. 10 12. Preparation according to any one of claims 1 to 10, characterized in that the total concentration of polysaccharides in the gel is in the range of 1 to 5% by weight, preferably in the range of 4 to 5 % in weight.